{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:10:41Z","timestamp":1791216641082,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-02038-9","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T03:23:51Z","timestamp":1741749831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Leveraging microbiome signatures to predict tumor immune microenvironment and prognosis of patients with endometrial carcinoma"],"prefix":"10.1007","volume":"16","author":[{"given":"Yuting","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuchen","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanbing","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"2038_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"2038_CR2","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3760\/cma.j.cn112152-20220922-00647","volume":"45","author":"RS Zheng","year":"2023","unstructured":"Zheng RS, Zhang SW, Sun KX, et al. Cancer statistics in China, 2016. Zhonghua Zhong Liu Za Zhi. 2023;45:212\u201320. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20220922-00647.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"2038_CR3","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/jcsm.12402","volume":"10","author":"MS Anker","year":"2019","unstructured":"Anker MS, Holcomb R, Muscaritoli M, et al. Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review. J Cachexia Sarcopenia Muscle. 2019;10:22. https:\/\/doi.org\/10.1002\/jcsm.12402.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2038_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","volume":"20","author":"V Makker","year":"2019","unstructured":"Makker V, Rasco D, Vogelzang NJ, et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019;20:711\u20138. https:\/\/doi.org\/10.1016\/S1470-2045(19)30020-8.","journal-title":"Lancet Oncol"},{"key":"2038_CR5","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1053\/j.gastro.2020.11.041","volume":"160","author":"V Matson","year":"2021","unstructured":"Matson V, Chervin CS, Gajewski TF. Cancer and the microbiome\u2014influence of the commensal microbiota on cancer, immune responses, and immunotherapy. Gastroenterology. 2021;160:600\u201313. https:\/\/doi.org\/10.1053\/j.gastro.2020.11.041.","journal-title":"Gastroenterology"},{"key":"2038_CR6","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1146\/annurev-immunol-051116-052133","volume":"35","author":"A Dzutsev","year":"2017","unstructured":"Dzutsev A, Badger JH, Perez-Chanona E, et al. Microbes and cancer. Annu Rev Immunol. 2017;35:199\u2013228. https:\/\/doi.org\/10.1146\/annurev-immunol-051116-052133.","journal-title":"Annu Rev Immunol"},{"key":"2038_CR7","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1126\/science.aaa4972","volume":"348","author":"WS Garrett","year":"2015","unstructured":"Garrett WS. Cancer and the microbiota. Science. 2015;348:80. https:\/\/doi.org\/10.1126\/science.aaa4972.","journal-title":"Science"},{"key":"2038_CR8","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.trecan.2019.12.007","volume":"6","author":"AG Ram\u00edrez-Labrada","year":"2020","unstructured":"Ram\u00edrez-Labrada AG, Isla D, Artal A, et al. The influence of lung microbiota on lung carcinogenesis, immunity, and immunotherapy. Trends Cancer. 2020;6:86\u201397. https:\/\/doi.org\/10.1016\/j.trecan.2019.12.007.","journal-title":"Trends Cancer"},{"key":"2038_CR9","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1007\/s13238-020-00813-8","volume":"12","author":"A Wong-Rolle","year":"2020","unstructured":"Wong-Rolle A, Wei HK, Zhao C, Jin C. Unexpected guests in the tumor microenvironment: microbiome in cancer. Protein Cell. 2020;12:426. https:\/\/doi.org\/10.1007\/s13238-020-00813-8.","journal-title":"Protein Cell"},{"key":"2038_CR10","doi-asserted-by":"publisher","first-page":"2333790","DOI":"10.1080\/19490976.2024.2333790","volume":"16","author":"N Wang","year":"2024","unstructured":"Wang N, Zhang L, Leng X-X, et al. Fusobacterium nucleatum induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the Hippo pathway. Gut Microb. 2024;16:2333790. https:\/\/doi.org\/10.1080\/19490976.2024.2333790.","journal-title":"Gut Microb"},{"key":"2038_CR11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.immuni.2015.01.010","volume":"42","author":"C Gur","year":"2015","unstructured":"Gur C, Ibrahim Y, Isaacson B, et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity. 2015;42:344\u201355. https:\/\/doi.org\/10.1016\/j.immuni.2015.01.010.","journal-title":"Immunity"},{"key":"2038_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.tim.2015.03.009","volume":"23","author":"NO Kaakoush","year":"2015","unstructured":"Kaakoush NO, Casta\u00f1o-Rodr\u00edguez N, Man SM, Mitchell HM. Is Campylobacter to esophageal adenocarcinoma as Helicobacter is to gastric adenocarcinoma? Trends Microbiol. 2015;23:455\u201362. https:\/\/doi.org\/10.1016\/j.tim.2015.03.009.","journal-title":"Trends Microbiol"},{"key":"2038_CR13","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1128\/IAI.03012-14","volume":"83","author":"NO Kaakoush","year":"2015","unstructured":"Kaakoush NO, Deshpande NP, Man SM, et al. Transcriptomic and proteomic analyses reveal key innate immune signatures in the host response to the gastrointestinal pathogen Campylobacter concisus. Infect Immun. 2015;83:832\u201345. https:\/\/doi.org\/10.1128\/IAI.03012-14.","journal-title":"Infect Immun"},{"key":"2038_CR14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/humrep\/deaa372","volume":"36","author":"A Sola-Leyva","year":"2021","unstructured":"Sola-Leyva A, Andr\u00e9s-Le\u00f3n E, Molina NM, et al. Mapping the entire functionally active endometrial microbiota. Hum Reprod Oxf Engl. 2021;36:1021\u201331. https:\/\/doi.org\/10.1093\/humrep\/deaa372.","journal-title":"Hum Reprod Oxf Engl"},{"key":"2038_CR15","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13073-016-0368-y","volume":"8","author":"MRS Walther-Ant\u00f3nio","year":"2016","unstructured":"Walther-Ant\u00f3nio MRS, Chen J, Multinu F, et al. Potential contribution of the uterine microbiome in the development of endometrial cancer. Genome Med. 2016;8:122. https:\/\/doi.org\/10.1186\/s13073-016-0368-y.","journal-title":"Genome Med"},{"key":"2038_CR16","doi-asserted-by":"publisher","first-page":"1202454","DOI":"10.3389\/fmicb.2023.1202454","volume":"14","author":"X Deng","year":"2023","unstructured":"Deng X, Chen X, Luo Y, et al. Intratumor microbiome derived glycolysis-lactate signatures depicts immune heterogeneity in lung adenocarcinoma by integration of microbiomic, transcriptomic, proteomic and single-cell data. Front Microbiol. 2023;14:1202454. https:\/\/doi.org\/10.3389\/fmicb.2023.1202454.","journal-title":"Front Microbiol"},{"key":"2038_CR17","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea G, Mlecnik B, Tosolini M, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782\u201395. https:\/\/doi.org\/10.1016\/j.immuni.2013.10.003.","journal-title":"Immunity"},{"key":"2038_CR18","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","volume":"48","author":"V Thorsson","year":"2018","unstructured":"Thorsson V, Gibbs DL, Brown SD, et al. The immune landscape of cancer. Immunity. 2018;48:812. https:\/\/doi.org\/10.1016\/j.immuni.2018.03.023.","journal-title":"Immunity"},{"key":"2038_CR19","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.54659","volume":"9","author":"B Ricci","year":"2020","unstructured":"Ricci B, Tycksen E, Celik H, et al. Osterix-Cre marks distinct subsets of CD45- and CD45+ stromal populations in extra-skeletal tumors with pro-tumorigenic characteristics. Elife. 2020;9: e54659. https:\/\/doi.org\/10.7554\/eLife.54659.","journal-title":"Elife"},{"key":"2038_CR20","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.18632\/aging.205447","volume":"16","author":"S-W Lai","year":"2024","unstructured":"Lai S-W, Cheng Y-C, Kiu K-T, et al. PROX1 interaction with \u03b1-SMA-rich cancer-associated fibroblasts facilitates colorectal cancer progression and correlates with poor clinical outcomes and therapeutic resistance. Aging (Albany NY). 2024;16:1620\u201339. https:\/\/doi.org\/10.18632\/aging.205447.","journal-title":"Aging"},{"key":"2038_CR21","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","volume":"18","author":"ST Paijens","year":"2021","unstructured":"Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2021;18:842\u201359. https:\/\/doi.org\/10.1038\/s41423-020-00565-9.","journal-title":"Cell Mol Immunol"},{"key":"2038_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020. https:\/\/doi.org\/10.1038\/s41423-020-0488-6.","journal-title":"Cell Mol Immunol"},{"key":"2038_CR23","doi-asserted-by":"publisher","first-page":"100336","DOI":"10.1016\/j.esmoop.2021.100336","volume":"7","author":"M Palmeri","year":"2022","unstructured":"Palmeri M, Mehnert J, Silk AW, et al. Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers. ESMO Open. 2022;7:100336. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100336.","journal-title":"ESMO Open"},{"key":"2038_CR24","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1016\/j.cell.2022.02.027","volume":"185","author":"A Fu","year":"2022","unstructured":"Fu A, Yao B, Dong T, et al. Tumor-resident intracellular microbiota promotes metastatic colonization in breast cancer. Cell. 2022;185:1356-1372.e26. https:\/\/doi.org\/10.1016\/j.cell.2022.02.027.","journal-title":"Cell"},{"key":"2038_CR25","doi-asserted-by":"publisher","first-page":"1301506","DOI":"10.3389\/fimmu.2023.1301506","volume":"14","author":"J Wu","year":"2024","unstructured":"Wu J, Zhang P, Mei W, Zeng C. Intratumoral microbiota: implications for cancer onset, progression, and therapy. Front Immunol. 2024;14:1301506. https:\/\/doi.org\/10.3389\/fimmu.2023.1301506.","journal-title":"Front Immunol"},{"key":"2038_CR26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1093\/humupd\/dmy048","volume":"25","author":"R Koedooder","year":"2019","unstructured":"Koedooder R, Mackens S, Budding A, et al. Identification and evaluation of the microbiome in the female and male reproductive tracts. Hum Reprod Update. 2019;25:298\u2013325. https:\/\/doi.org\/10.1093\/humupd\/dmy048.","journal-title":"Hum Reprod Update"},{"key":"2038_CR27","first-page":"384","volume":"66","author":"PK Heinonen","year":"1985","unstructured":"Heinonen PK, Teisala K, Punnonen R, et al. Anatomic sites of upper genital tract infection. Obstet Gynecol. 1985;66:384\u201390.","journal-title":"Obstet Gynecol"},{"key":"2038_CR28","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.3390\/biology11111683","volume":"11","author":"R Siddiqui","year":"2022","unstructured":"Siddiqui R, Makhlouf Z, Alharbi AM, et al. The gut microbiome and female health. Biology. 2022;11:1683. https:\/\/doi.org\/10.3390\/biology11111683.","journal-title":"Biology"},{"key":"2038_CR29","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","volume":"30","author":"M St Paul","year":"2020","unstructured":"St Paul M, Ohashi PS. The roles of CD8+ T cell subsets in antitumor immunity. Trends Cell Biol. 2020;30:695\u2013704. https:\/\/doi.org\/10.1016\/j.tcb.2020.06.003.","journal-title":"Trends Cell Biol"},{"key":"2038_CR30","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.it.2022.08.004","volume":"43","author":"S Ma","year":"2022","unstructured":"Ma S, Caligiuri MA, Yu J. Harnessing IL-15 signaling to potentiate NK cell-mediated cancer immunotherapy. Trends Immunol. 2022;43:833\u201347. https:\/\/doi.org\/10.1016\/j.it.2022.08.004.","journal-title":"Trends Immunol"},{"key":"2038_CR31","doi-asserted-by":"publisher","first-page":"101804","DOI":"10.1016\/j.mcp.2022.101804","volume":"62","author":"J Zhang","year":"2022","unstructured":"Zhang J, Ping Y, Zhao Q, et al. BPIFB2 is highly expressed in \u201ccold\u201d lung adenocarcinoma and decreases T cell chemotaxis via activation of the STAT3 pathway. Mol Cell Probes. 2022;62:101804. https:\/\/doi.org\/10.1016\/j.mcp.2022.101804.","journal-title":"Mol Cell Probes"},{"key":"2038_CR32","doi-asserted-by":"publisher","first-page":"1239875","DOI":"10.3389\/fimmu.2023.1239875","volume":"14","author":"Y Li","year":"2023","unstructured":"Li Y, Wu Q, Lv J, Gu J. A comprehensive pan-cancer analysis of CDH5 in immunological response. Front Immunol. 2023;14:1239875. https:\/\/doi.org\/10.3389\/fimmu.2023.1239875.","journal-title":"Front Immunol"},{"key":"2038_CR33","doi-asserted-by":"publisher","first-page":"8489","DOI":"10.3390\/ijms23158489","volume":"23","author":"L Xu","year":"2022","unstructured":"Xu L, Shao F, Luo T, et al. Pan-cancer analysis identifies CHD5 as a potential biomarker for glioma. Int J Mol Sci. 2022;23:8489. https:\/\/doi.org\/10.3390\/ijms23158489.","journal-title":"Int J Mol Sci"},{"key":"2038_CR34","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.annonc.2024.02.006","volume":"35","author":"G Bogani","year":"2024","unstructured":"Bogani G, Monk BJ, Powell MA, et al. Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer. Ann Oncol Off J Eur Soc Med Oncol. 2024;35:414\u201328. https:\/\/doi.org\/10.1016\/j.annonc.2024.02.006.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"2038_CR35","doi-asserted-by":"publisher","first-page":"109978","DOI":"10.1016\/j.cbi.2022.109978","volume":"361","author":"J-T Chiou","year":"2022","unstructured":"Chiou J-T, Lee Y-C, Wang L-J, Chang L-S. BCL2 inhibitor ABT-199 and BCL2L1 inhibitor WEHI-539 coordinately promote NOXA-mediated degradation of MCL1 in human leukemia cells. Chem Biol Interact. 2022;361:109978. https:\/\/doi.org\/10.1016\/j.cbi.2022.109978.","journal-title":"Chem Biol Interact"},{"key":"2038_CR36","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2147\/OTT.S226951","volume":"13","author":"S-H Sohn","year":"2020","unstructured":"Sohn S-H, Kim B, Sul HJ, et al. Foretinib inhibits cancer stemness and gastric cancer cell proliferation by decreasing CD44 and c-MET signaling. OncoTargets Ther. 2020;13:1027\u201335. https:\/\/doi.org\/10.2147\/OTT.S226951.","journal-title":"OncoTargets Ther"},{"key":"2038_CR37","doi-asserted-by":"publisher","first-page":"7058","DOI":"10.1038\/s41598-020-63996-4","volume":"10","author":"E Lee","year":"2020","unstructured":"Lee E, Yeo S-Y, Lee K-W, et al. New screening system using Twist1 promoter activity identifies dihydrorotenone as a potent drug targeting cancer-associated fibroblasts. Sci Rep. 2020;10:7058. https:\/\/doi.org\/10.1038\/s41598-020-63996-4.","journal-title":"Sci Rep"},{"key":"2038_CR38","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41571-023-00852-0","volume":"21","author":"AJ Hanrahan","year":"2024","unstructured":"Hanrahan AJ, Chen Z, Rosen N, Solit DB. BRAF\u2014a tumour-agnostic drug target with lineage-specific dependencies. Nat Rev Clin Oncol. 2024;21:224\u201347. https:\/\/doi.org\/10.1038\/s41571-023-00852-0.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02038-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-02038-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-02038-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T15:04:15Z","timestamp":1741791855000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-02038-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2038"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-02038-9","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"assertion":[{"value":"20 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"299"}}